Additional examples include anti-IFN-I autoAbs that can reduce SLE severity [302], anti-human epidermal growth factor receptor 2 (HER2) autoAbs that increase breast cancer patients’ survival rate [303], and anti-amyloidogenic peptides autoAbs that protect against AD [304]. This evidence concerns the gene ERBB2 and breast carcinoma.